Pharmaceutical Substances Syntheses, Patents, Applications - Part 168 pptx

Pivmecillinam P 167 1 Reference(s): DE 1795 423 (Lovens; 2.5.1972; prior. 27.9.1968). US 3 660 575 (Lovens; 2.5.1972; prior. 26.9.1968). US 3 697 507 (Lovens Kern. Fabr.; 10.10.1972; appl. 26.9.1968; GB-prior. 29.9.1967). GB 1 215 812 (Lovens Kem. Fabr.; appl. 29.9.1967; valid from 27.9.1968). DAS 1 795 702 (Loevens; appl. 27.9.1968; GB-prior. 10.1 1.1967, 3.1.1968,22.3.1968). DAS 1 795 713 (Loevens; appl. 27.9.1968; GB-prior. 29.9.1967, 5.10.1967, 23.10.1967, 10.1 I .l967, 6.12.1967, 3.1.1968, 22.3.1968). crystalline,form: US 3 956 279 (Leo; I 1 S.1976; appl. 21.9.1973). DAS 2 349 971 (Leo; appl. 4.10.1973; GB-prior. 6.10.1972). Fornzulation(s): susp. 175 mg; tabl. 350 mg, 500 mg (as hydrochloride) Trade Name(s): D: Berocillin (Thomae; 1972); Miraxidl-K (Rorer)-comb.; I: Pondocillina (Sigma-Tau); wfrn wfrn wfrn Maxifen (Sharp & Dohrnel Uro Berocillin (Thomae)- Boehringer Mannh.; 1972); comb.; wfm wfrn F: Proampi (Leo) Pivmecillinam ATC: JOlCA08 Use: antibiotic RN: 32886-97-8 MF: C2,H,,N,0sS MW: 439.58 EINECS: 251-276-6 CN: [2S-(2a,5a,6~)]-6-[[(hexahydro-1H-azepin-1-yl)methylene]arnino]-3,3-dimethyl-7-oxo-4-thia-l- azabicyclo[3.2.0]heptane-2-carboxylic acid (2,2-dirnethyl-1-oxopropoxy)methyl ester hydrochloride RN: 32887-03-9 MF: C2,H3,N305S . HCI MW: 476.04 6-arninapenicillanic chlorornethyl acid sodium salt pivolote I * 3, hexahydroazepine-1-carbaxoldehyde, oxalyl chlaride pivaloyloxymethyl 6-amino- penicillanate tosylate (1) Pivmecillinam I 1672 P Pizotifen Reference(s): DOS 2 055 53 1 (Loevens; appl. I 1.1 1.1970; GB-prior. 11 .I 1.1969, 8.7.1970). GB 1 293 590 (Loevens; appl. 11.1 1.1969, 8.7.1970; valid from 10.11.1970). US 3 957 764 (Loevens; 18.5.1976; GB-prior. 11.11.1969,8.7.1970). combination with trimethoprim: US 4 076 816 (Leo; 28.2.1978; GB-prior. 17.5.1974). For~nulation(s): gran. 100 mg; tabl. 50 mg, 200 mg (as hydrochlondc) Trade Name(s): D: Miraxid-K (Rorer; 1984)- F: Selexid (Leo; 1984) Selexid (Leo); wfm comb.; wfm GB: Miraxid (Leo)-comb.; wfm J: Mclycin (Takeda; 1979) Pizotifen (Pi zotyline) ATC: N02CXOI Use: antimigraine agent RN: 15574-96-6 MF: C,,H,,NS MW: 295.45 EINECS: 239-632-9 LD,,,: 410 mglkg (R, p.0.) CN: 4-(9,10-dihydro-4H-henzo[4,5]cyclohepta[l,2-b]thien-4-ylidene)-l-methylpiperidine malea te (1:l) RN: 5 189-1 1-7 MF: C,,H,,NS . C4H,0S MW: 429.54 EINECS: 225-970-4 LD,,; 43 mgfkg (M, i.v.); 17 mglkg (R, i.v.) CY NoOCOCH,. HOOC 0 1 -methyl-2- n - pyrrolidone phtholic 2-thienyl- anhydride acetic acid polyphosphoric acid 1-4373 0 I HCI, CH3 CH3COOH , -1 1-methyl-4- HO magnesium \ chloride '33 Refererzce(s): BE 636 717 (Sandoz; appl. 28.8.1963; CH-prior. 31.8.1962, 8.7.1963). US 3 272 826 (Sandoz; 13.9.1966; CH-prior. 31.8.1962). Formulation(s): drg. 0.5 mg, 1.5 mg; syrup 0.5 mg/lO ml (as maleate) Plaunotol P 1673 Trade Name(s): D: Mosegor (Novartis Pharma) GB: Sanomigran (Novartis) US A: Sandomigran (Sandoz); Sandomigran (Novartis I: Sandomigran (Novartis wfm Pharma) Farma) F: Sanmigran (Novartis) Plaunotol ATC: A02B Use: peptic ulcer therapeutic RN: 64218-02-6 MF: C20Hqd02 MW: 306.49 LD,,: 83 mgkg(M,i.v.); 8.1 glkg(M, p.0.); 10.9 glkg (R, p.0.) CN: (Z,E,~-2-(4,8-dimethyl-3,7-nonadienyl)-6-methyl-2,6-octadiene-l,8-diol I Plaunotot I Isolation by extraction of Croton sublyratus or Crvtvn colmnaris and purification on silica gel. Referenceis I: Ogiso, A. et al.: Chem. Pharm. Bull. (CPBTAL) 26, 31 17 (1978). US 4 059 641 (Sankyo; 22.1 1.1977; prior. 18.1 1.1975). total .qnthesis: CH 629 471 (Sankyo; appl. 18.1 1.1976; USA-prior. 18.1 1.1975). US 4 151 357 (Sankyo; 24.4.1979; J-prior. 24.4.1976). Formulation(s): cps. 50 mg Trade Nameis): J: Kelnac (Sankyo) Polaprezinc (CAZ; Z- 103) RN: LD,,: CN: 107667-60-7 MF: C,H,,N40,Zn MW: 289.61 1269 mgikg (M, p.0.); 7375 mgkg (R, p.0.) [N-P-alanyl-L-histidinato(2-)-N,~,Oa]zinc ATC: A02B Use: hepatic protectant, ulcer therapeutic, anti-helicobacter pylori 1674 P Polidocanol R<ferrnr~(s): Yoshikawa, T.; Naito, Y.; Tanigawa, T.; Yoneta, T.; Kondo, M.: Biochim. Biophys. Acta (BBACAQ) 1115 (I), 15 (1991). synthesis: WO 8 800 048 (Zeria Pharmaceutical Co.; appl. 14.1.1988; J-prior. 3.7.1986). EP 303 380 (Hamari Chemicals; appl. 15.2.1989; J-prior. 10.8.1987). pharmaceuticul compositions with cyclodextrins: WO 9 525 513 (Bellera Medical Products; appl. 28.9.1995; 18.3.1994). oral pharmaceutical compositions: WO 9 015 616 (Zeria Pharmaceutical Co.; 27.12.1990; J-prior. 15.6.1989). EP 466 029 (Zeria Pharmaceutical Co.; appl. 15.1.1992; J-prior. 6.7.1990). Trade Narne(s): J: Promac (Zeria) Polidocanol (Hydroxypolyethoxydodecane) ATC: C05BB02 Use: local anesthetic, agent for sclerotherapy of varicose veins RN: 3055-99-0 MF: C,,H,,O,, MW: 582.82 EINECS: 221-284-4 CN: 3,6,9,l2,l~,l8,2l,24,2~-nonaoxanonatriacontan-l-ol 1 -dodecanol ethylene oxide Polidocanol Scholler, C.: Angew. Chem. (ANCEAD) 62,7 (1950). Pertsemlides, D.; Soehring, K.: Arzneim Forsch. (ARZNAD) 10,990 (1960). Formulation(s): amp. 0.5 %, 1 %, 2 %, 3 %, 4 %; cream 5 g/100 g; ointment 30 mg/g, 5 g/100 g; suppos. 10 rng Trade Name(s): D: Aethoxysklerol numerous generics and GB: Alcos-Anal (Norgine)- (Kreussler)-comb. combination preparations comb.; wfm Recessan (Kreussler) F: Aetoxiscltrol (Dexo) I: Atossisclerol (Also) Polymyxin B ATC: A07AA05; JOl XB02; SOIAA18; S02AAl 1; S03AA03 Use: antibiotic (macrocyclic peptide) RN: 1404-26-8 MF: unspecified MW: unspecified EINECS: 215-768-4 LD,,,: 3980 pglkg (M, 1.v.) CN: polymyxin B sulfate RN: 1405-20-5 MF: H$O, . x unspecified MW: unspecified EINECS: 215-774-7 LD,,,: 5400 pg (M, i.v.); 790 mg (M, p.0.) Polythiazide P 1675 -'NH, Polymyxin 8 Polymyxin 8, Polymyxin 8, Cyclopolypeptide antibiotic from cultures of Bacilluspolymyxa. Reference(s): US 2 565 057 (Burroughs Wellcome; 1951; GB-prior. 1946). US 2 595 605 (American Cyanamid; 1952; appl. 1948). US 2 771 397 (US-Secretary of Agriculture; 1956; prior. 1930). Formulation(s): ophthalmic ointment 10000 idg; sol./drops 10000 iu; tabl. 20 mg (200000 iu), 25 mg (250000 iu) (as sulfate); vial 50 mg Trade Name(s): D: Polymyxin-B (Pfizer) numerous generics and combination preparations F: Antibiotulle Lumikre (Solvay Pharma)-comb. Maxidol (A1con)-comb. Primyxine (Thera France)- comb. StCrimycine (CIBA - Vision)-comb. numerous combination preparations GB: Gregoderm (Unigreg)- comb. Maxitrol (A1con)-comb. Neosporin (Dominion)- comb. Otosporin (Glaxo Wellcome)-comb. Polyfax (Dominion)-comb. Polytrim (Dominion)- comb. I: Anauran (Zambon Farm.)- comb. Localyn Oto (Recordati) comb. Mixotone (Teofarma)- comb. Otosporia (Warner- Lambert)-comb. J: Polymyxin B sulfate (Pfizer) USA: Betadine (Purdue Frederick)-comb. Cortisporin (Monarch)- comb. Lazersporin-C (Pedino1)- comb. Neosporin (Glaxo Wellcome)-comb. Pediotic (Monarch; as sulfate)-comb. Polysporin (Warner- Lambeft)-comb. Polytrim (Allergan)-comb. Terramycin (Pfizer; as sulfate)-comb. Polythiazide ATC: C03AA05 Use: diuretic RN: 346-18-9 MF: C,,H,3ClF,N30,S3 MW: 439.89 EINECS: 206-468-4 LDs,: >5 g/kg (M, p.0.); >10 mglkg (R, p.0.); 450 mglkg (dog, p.0.) CN: 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-l,2,4-benzothiadiazine-7- sulfonamide 1,l -dioxide 1676 P Potassium canrenoate 4-aminosulfonyl-5-chloro- (2.2.2-trifluoroethyl- I Polythiaride 2-methylaminosulfanyl- thio)acetoldehyde oniline dimethyl acetal Reference (s): US 3 009 911 (Pfizer: 21.1 1.1961; appl. 4.1.1961; prior. 3.6.1960). Forrnulation(s): . cps 0.5 mg (in comb. with prazosin.HC1); tabl. 0.25 mg, 0.5 mg, 1 mg (as hydrochloride) Trade Name(s): D: Polypressl-forte (Pfizer)- Rtnbse (Pfizer); wfm I JSA: Minizide (Pfizer)-comb. comb. GB: Nephril (Pfizer) F: Envarkse (Pfizcr)-comb.; J: Polyregulon (Yamanouchi) wfm Renese (Taito Pfixr) Potassium canrenoate ATC: C03DA02 Use: aldostcrone antagonist, diuretic RN: 21 81-04-6 MF: C22H,,K0, MW: 396.57 EINECS: 21 8-554-9 LD,,: 125 mglkg (M, i.v.); 740 mgkg (M, p.0.); 112 mglkg (R, i.v.); 650 mgkg (R, p.0.) CN: (l7a)- 17-hydroxy-3-oxopregna-4,6-diene-2l-carboxylic acid monopotassium salt canrenone RN: 976-71-6 MF: CZ2H2,O, MW: 340.46 EINECS: 213-554-5 LD,,,: >5 glkg (R, p.0.) do oCe , xytene, Tos-oH Me H b ri ri chloranil 0 ' 0 3-(17P-hydroxy-3-0x0- 4-ondrosten- 17-yl)- propionic ocid lactone (cf. spironolactone synthesis) canrenone (I) Potossium conrenoote Prajmalium bitartrate P 1677 Reference(s): US 3 013 012 (Searle; 12.12.1961; prior. 22.12.1960, 12.12.1958). US 2 900 383 (Searle; 18.8.1959; appl. 18.12.1957). Cella, J.A.; Tweit, R.C.: J. Org. Chem. (JOCEAH) 24, 1109 (1959). starting material: Cella, J.A. et al.: J. Org. Chem. (JOCEAH) 24,743 (1959) (spironolactone, q. v.). injection solutions: US 4 088 759 (Boehringer Mannh.; 9.5.1978; D-prior. 12.12.1975). Woog, M. et al.: Pharm. Ind. (PHINAN) 40, 1371 (1978). Formulation(s): amp. 200 mg/lO ml; tabl. 25 mg, 50 mg, 75 mg, 100 mg Trade Name(s): D: Aldactone (Boehringer Phanurane (Specia); wfm Luvion (Gienne Pharma) Mannh.) Soludactone (Monsanto) Venactone (Lepetit) Kalium-Can ratiopharm GB: Spiroctan-M (Boehringer J: Soldactone (Dainippon) (ratiopharm) Mannh.) USA: Soldactone (Searle); wfm Osyrol pro inj. (Hoechst) I: Kadiur (Gienne Pharma)- F: Aldatense (Sear1e)-comb.; comb. wfm Kanrenol (GNR) Prajmalium bitartrate AX: COlBA08 Use: antiarrhythmic RN: 2589-47-1 MF: C2,H3,N202. C,H,O, MW: 518.61 EINECS: 219-975-0 LD,,: 1700 ~g/kg (M, i.v.); 43 mg/kg (M, p.0.); 3400 @kg (R, i.v.); 54 mglkg (R, p.0.) CN: (17R,21a)-17,21-dihydroxy-4-propylajmalanium salt with [R-(R*,R*)]-2,3-dihydroxybutanedioic acid HO, P~~PYI bromide prajmalium bromide HO, prajmalium hydroxide L-tartaric I Prajmalium bitartrate (aldehyde base) (I) acid I 1678 P Pralidoxime iodide Reference(s1: DE 1 154 120 (Thomae; appl. 10.1.1962). DE 1 196 207 (Thomae; appl. 5.7.1963; USA-prior. 17.12.1962). US 3 414 577 (Boehringer Ing.; 3.12.1968; appl. 17.12.1962, 23.7.1964, 7.10.1965; D-prior. 10.1.1962) firmululion(s1: f. c. tabl. 20 mg; tabl. 20 mg Trade Narne(s): D: Neo-Gilurytmal (Solvay I: Neoaritmina (Solvay Arzneimi ttel) Pharma) Pralidoxime iodide ATC: V03AB04 Use: antidote (against anticholinesterase- alkylphosphate), cholinesterase reactivator RN: 94-63-3 MF: C7H91N,0 MW: 264.07 EINECS: 202-349-6 LD,,,: 145 mgfkg (M, i.v.1; 1.500 mgkg (M, p.0.); 178 mglkg (R, i.v.) CN: 2-[(hydroxyimino)methyl]-I-methylpyridinium iodide hydroxide RN: 495-94-3 MF: C7H,,N202 MW: 154.17 mesylate RN: 154-97-2 MF: C7H9N,0. CH,O,S MW: 232.26 EINECS: 205-839-8 LD,,,: 118 mgkg (M, i.v.); 3700 mglkg (M, p.0.); 109 mgkg (R, i.v.); 7 gkg (R, p.0.) chloride RN: 51-15-0 MF: C7H9CIN20 MW: 172.62 EINECS: 200-080-9 LD,,,: 90 mgkg (M, i.v.); 4100 mglkg (M, p.0.); 96 mgkg (R, i.v.) **,O"N/OH hydroxyl- methyl amine iodide pyridine-2- pyridine-2- Prolidoxime iodide carboxaldehyde corboxoldehyde mime Reference(s): US 2 816 113 (US-Secretary of the Army; 1957; appl. 1956). allernalive syntheses: US 3 123 61 3 (Campbell Pharmac.; 3.3.1964; appl. 5.5.1961). US 3 140 289 (US-Secretary of the Army; 7.7.1964; appl. 11.4.1962). US 3 155 674 (Oh Mathieson; 3.1 1.1964; appl. 19.1 1.1962). sfubilizarion of aqueous solurions: EP 46 685 (Survival Technology; appl. 25.8.1981; USA-prior. 26.8.1980) Forwzulation(s): amp. 200 mgIl0 ml (as mesylate); vial 1 g120 ml (as chloride) Pramipexole hydrochloride P 1679 Trade Name(s): F: Contrathion (Serb; as I: Contrathion (Rhbne- USA: Protopam (Wyeth-Ayerst; methyl sulfate) Poulenc Rorer; as as chloride) mesylate) Pramipexole hydrochloride (SND-919Y) ATC: N04BC05 Use: dopamine D,-agonist RN: 104632-25-9 MF: C,,H,,N,S . 2HCl MW: 284.26 CN: (S)-4,5,6,7-Tetrahydro-N6-propyl-2,6-benzothiazoldiane dihydrochloride (S)-base RN: 104632-26-0 MF: C,,,H1,N3S MW: 21 1.33 (S)-dihydrochIoride hydrate RN: 191217-81-9 MF: C,,HI7N3S .2HC1 . H20 MW: 302.27 (*)-base RN: 104617-86-9 MF: C,,HI7N3S MW: 211.33 (*)-dihydrochIoride RN: 104617-85-8 MF: C,,H,,N3S . 2HCI MW: 284.26 r - toluene,^ c N CH, . A 'YY - HCI OH 0 phthalic 4-aminocyclo- anhydride hexanol hydrochloride 4-(phthalirnid0)- cyclohexanal (1) 1. Br2. HBr, CH,COOH K2Cr207. H20. H SO4. CHCl 2. H2N A NH2, CH,COOH 1 , 11 potassium dichromate 4-(phthoCmid0)- cyclohexanone 1. HZN-NH2 . H20, C2H,0H 2. L-(+)-tartaric acid -NH2 1. hydrozine hydrate 2. rocemate resalution (?)-2-amino-6-phthal- (S)-(-)-2.6-diamino- irnida-4.5.6,7-tetra- 4,5,6,7-tetrahydro- hydrabenzothiazole (11) benzothiazale (Ill) 1. DMF 2. NaBH, 3. HCi m + H,C'"CHO 2. sodium propionaldehyde (N) bo'oh~dride Pramipexale hydrochloride 1680 P Pramiracctam hydrochloride ,Jl. . L'n3C;uun H.C CH, u l-ocetomido- cyclohexanone 1. N, DMF 2. NoBH4 3. HCI or (+)-6-acetomido-2- amino-4.5.6,7-tetra- hydrobenzothiozole (V) Reference(s): EP 186 087 (Thomae GmbH; appl. 16.12.1985; D-prior. 22.12.1984). Schneider, G.S.; Mierau, J.: J. Med. Chem. (JMCMAR) 30,494 (1987). Formulatiun(s): tahl. 0.088 rng, 0.1 25 mg, 0.18 mg, 0.25 rng, 0.7 rng, '1.0 (as dihydrochloride hydrate) Trade Narne(s): D: Sifrol (Boehringer USA: Mirapex (Boehringer Ingelheim) Ingelheim; Pharmacia & Upjohn) Pramiracetam hydrochloride ATC: N06BX16 Usc: nootropic RN: 75733-50-5 MF: C14H,N30,. HCI MW: 305.85 CN: N-[2-[Bis(l-methy lethyl)amino]ethyl]-2-0x0-1-pyrrolidineacetamide hydrochloride base RN: 68497-62-1 MF: C,4HzN302 MW: 269.39 sulfate RN: 72869-16-0 MF: C14H2,N,0,. H,S04 MW: 367.47 2-pyrroli- ethyl P-bromo- dinone ocetote ethyl 2-oxo-l- pyrrolidineocetote (I) . 25 1-2 7 6-6 CN: [2S-(2a,5a,6~) ]-6 -[ [(hexahydro-1H-azepin-1-yl)methylene]arnino ]-3 ,3-dimethyl-7-oxo-4-thia-l- azabicyclo[3.2.0]heptane-2-carboxylic acid (2,2-dirnethyl-1-oxopropoxy)methyl ester. 6-chloro-3,4-dihydro-2-methyl- 3-[ [(2,2,2-trifluoroethyl)thio]methyl ]-2 H-l,2,4-benzothiadiazine- 7- sulfonamide 1,l -dioxide 1676 P Potassium canrenoate 4-aminosulfonyl-5-chloro- (2.2.2-trifluoroethyl-. 4-( phthoCmid0 )- cyclohexanone 1. HZN-NH2 . H20, C2H,0H 2. L-(+)-tartaric acid -NH2 1. hydrozine hydrate 2. rocemate resalution (? )-2 -amino-6-phthal- (S )-( - )-2 .6-diamino- irnida-4.5.6,7-tetra-